Literature DB >> 10201945

Ectopic expression of DNA encoding IFN-alpha 1 in the cornea protects mice from herpes simplex virus type 1-induced encephalitis.

S Noisakran1, I L Campbell, D J Carr.   

Abstract

A novel approach to combat acute herpes simplex virus type 1 (HSV-1) infection has recently been developed by administration with a plasmid DNA construct encoding cytokine genes. Cytokines, especially type I IFNs (IFN-alpha and IFN-beta) play an important role in controlling acute HSV-1 infection. The purpose of the present study was to investigate the potential efficacy of ectopically expressed IFN-alpha 1 against ocular HSV-1 infection following in situ transfection of mouse cornea with a naked IFN-alpha 1-containing plasmid DNA. Topical administration of the IFN-alpha 1 plasmid DNA exerted protection against ocular HSV-1 challenge in a time- and dose-dependent manner and antagonized HSV-1 reactivation. In addition, IFN-alpha 1-transfected eyes expressed a fivefold increase in MHC class I mRNA over vector-treated controls. The protective efficacy of the IFN-alpha 1 transgene antagonized viral replication, as evidenced by the reduction of the viral gene transcripts (infected cell polypeptide 27, thymidine kinase, and viral protein 16) and viral load in eyes and trigeminal ganglia during acute infection. The administration of neutralizing Ab to IFN-alpha beta antagonized the protective effect of the IFN-alpha 1 transgene in mice. Collectively, these findings demonstrate the potential of using naked plasmid DNA transfection in the eye to achieve ectopic gene expression of therapeutically active agents.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10201945

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  Type I interferons and herpes simplex virus infection: a naked DNA approach as a therapeutic option?

Authors:  S Noisakran; D J Carr
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  RNA-dependent protein kinase is required for alpha-1 interferon transgene-induced resistance to genital herpes simplex virus type 2.

Authors:  Daniel J J Carr; Lisa Tomanek; Robert H Silverman; Iain L Campbell; Bryan R G Williams
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  High-level gene transfer to the cornea using electroporation.

Authors:  Kathleen Blair-Parks; Bonnie C Weston; David A Dean
Journal:  J Gene Med       Date:  2002 Jan-Feb       Impact factor: 4.565

4.  Alpha/Beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1.

Authors:  Bruno Sainz; William P Halford
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

5.  Herpes simplex virus type 2-mediated disease is reduced in mice lacking RNase L.

Authors:  Rebecca J Duerst; Lynda A Morrison
Journal:  Virology       Date:  2006-12-06       Impact factor: 3.616

6.  Repeated social stress enhances the innate immune response to a primary HSV-1 infection in the cornea and trigeminal ganglia of Balb/c mice.

Authors:  P Dong-Newsom; N D Powell; M T Bailey; D A Padgett; J F Sheridan
Journal:  Brain Behav Immun       Date:  2009-10-12       Impact factor: 7.217

Review 7.  Nonviral ocular gene therapy: assessment and future directions.

Authors:  Shannon M Conley; Xue Cai; Muna I Naash
Journal:  Curr Opin Mol Ther       Date:  2008-10

8.  Effect of undernourishment on Herpes Simplex Virus Type 1 ocular infection in the Wistar rat model.

Authors:  Fabian Benencia; Gisela Gamba; Ruben Benedetti; Maria C Courreges; Hernan Cavalieri; Ernesto J Massouh
Journal:  Int J Exp Pathol       Date:  2002-04       Impact factor: 1.925

9.  The antiviral efficacy of the murine alpha-1 interferon transgene against ocular herpes simplex virus type 1 requires the presence of CD4(+), alpha/beta T-cell receptor-positive T lymphocytes with the capacity to produce gamma interferon.

Authors:  Daniel J J Carr; Sansanee Noisakran
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

Review 10.  Gene Therapy in the Anterior Eye Segment.

Authors:  Cynthia Amador; Ruchi Shah; Sean Ghiam; Andrei A Kramerov; Alexander V Ljubimov
Journal:  Curr Gene Ther       Date:  2022       Impact factor: 4.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.